Xenon Pharmaceuticals Inc. XENE R2KR3KPHARMA

Q: What is the current share price of Xenon Pharmaceuticals Inc. (XENE)?

As of 2026-10-22 16:30 PDT, Xenon Pharmaceuticals Inc. (XENE) trades at $36.50 on NasdaqGM. Its 52-week range is $33.49 to $70.96.

Q: What is the market capitalisation of XENE?

Xenon Pharmaceuticals Inc. (XENE) has a market capitalisation of $3.53B on NasdaqGM.

Q: What is the P/E ratio of XENE?

XENE trades at a trailing price-to-earnings (P/E) ratio of -7.70. The industry average P/E is 25.61. Its price-to-book (P/B) ratio is 3.10.

Q: What is the return on equity (ROE) of XENE?

XENE has a return on equity (ROE) of -43.62%. Its return on capital employed (ROCE) is -63.09%.

Q: Is XENE a good stock to buy?

This page provides a data-driven analysis of Xenon Pharmaceuticals Inc. (XENE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · Canada

https://www.xenon-pharma.com

Company Profile ↓

$36.50

-3.11% 1Y

Mkt Cap$3.53B

P/E-7.70

P/B3.10

52W High$70.96

52W Low$33.49

Book Value$12.84

EPS (TTM)$-4.74

Company Overview

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Recent Developments

5-Year Trend Long-term compounding — revenue CAGR -5.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	-5.70%
1 Year:	-

Stock Price Performance

1 Year:	-3.11%
6 Months:	-34.13%
3 Months:	-44.21%
1 Month:	-0.16%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 8% of range

$33.49 $70.96

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
Death Cross8d ago
RSI (14)36.83 · Neutral

Price Performance

1M-0.16%

3M-44.21%

6M-34.13%

1Y-3.11%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

Revenue declined at -5.7% CAGR over 5 years.
Trading 48.6% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-7.70

Industry PE

25.61

Forward P/E

-7.61

PEG Ratio

Book Value

$12.84

Price to Book

3.10

P/S

inf

EV/EBITDA

-6.66

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

-5.70%

Profit 5Y

Revenue (YoY)

Earnings (YoY)

Profitability & Returns

ROCE

-63.09%

ROE

-43.62%

ROA

-28.02%

Profit Margin

0.00%

Op Margin

0.00%

Gross Margin

0.00%

EPS (Latest Qtr)

$-1.11

EPS (TTM)

$-4.74

Balance Sheet & Liquidity

Debt/Equity

0.52

Quick Ratio

20.71

Current Ratio

21.02

Debt

$6.42M

Total Assets

$1.30B

Current Assets

$1.11B

Working Capital

$518.86M

Ownership

Promoter Holding

0.16%

Chg in Prom Hold

0.05%

FII / Inst Holding

107.34%

Chg in FII Hold

-0.22%

Financial Snapshot

Enterprise Value

$3.53B

Total Revenue (TTM)

EBITDA

$-439.19M

Free Cash Flow

$-203.55M

Operating Cash Flow

$-337.52M

Shares Outstanding

96.84M

Gross Margin

0.00%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	XENE Xenon Pharmaceuticals Inc. R2KR3KPHARMA	36.50	-7.70	$3.53B	0.00%	-63.09%	-43.62%	-5.70%	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,306.69	43.95	$1.16T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	267.61	31.05	$644.91B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	285.19	80.56	$503.96B	2.54%	10.47%	-129.24%	1.75%	-29.06%
5	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	424.98	27.29	$381.46B	2.47%	9.74%	14.15%	10.40%	5.43%
6	MRK Merck & Co., Inc. SPXR3KPHARMA	147.24	117.79	$363.27B	2.31%	-	6.96%	5.64%	10.01%
7	NVS Novartis AG PHARMA	156.27	23.61	$297.02B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	172.57	25.80	$267.64B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	676.54	36.45	$250.15B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Dec 2014	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	264.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7.50M	0	0	0	0	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	80.24M	94.23M	96.34M	109.77M	112.33M	-
Operating Income	35.00K	-6.14M	199.00K	-820.00K	-2.60M	-5.66M	-6.37M	-7.33M	-5.46M	-7.99M	-7.89M	-8.64M	-8.05M	-7.81M	-7.59M	-14.19M	-11.76M	-10.51M	-8.95M	-8.03M	-646.00K	-9.70M	-16.06M	-22.50M	-15.60M	-17.37M	-30.32M	-38.13M	-49.05M	-55.62M	-55.68M	-59.04M	-69.10M	-73.68M	-72.74M	-94.23M	-96.34M	-109.77M	-112.33M	-123.16M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-72.08M	-93.60M	-95.69M	-109.16M	-111.74M	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-64.62M	-85.33M	-90.22M	-104.72M	-104.87M	-
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	427.00K	-626.00K	677.00K	538.00K	-2.57M	-
Net Income	-	-9.16M	1.17M	-3.83M	-3.94M	-3.26M	-6.02M	-7.71M	-6.00M	-7.52M	-7.38M	-7.74M	-8.06M	-3.75M	-7.80M	-14.38M	-11.34M	-10.01M	-8.87M	-7.48M	-175.00K	-8.86M	-15.76M	-22.11M	-15.45M	-19.67M	-31.16M	-37.15M	-41.73M	-47.46M	-48.46M	-47.93M	-57.92M	-62.79M	-65.05M	-84.71M	-90.90M	-105.26M	-102.30M	-110.74M
Diluted EPS	0.13	-0.64	-0.07	-0.27	-0.27	-0.23	-0.42	-0.51	-	-0.43	-0.41	-0.43	-0.45	-0.21	-0.45	-0.63	-0.42	-0.37	-	-	0.00	-	-	-0.51	-0.36	-0.35	-0.55	-0.57	-0.63	-0.72	-0.73	-0.62	-0.75	-0.81	-0.83	-1.07	-1.15	-1.31	-1.17	-1.11
R&D Expense	-	3.43M	3.67M	3.79M	-	4.36M	5.10M	5.96M	-	5.90M	6.11M	7.16M	-	5.57M	5.42M	6.25M	9.14M	8.21M	9.75M	11.79M	10.72M	13.04M	16.31M	18.38M	18.89M	19.36M	22.15M	29.43M	39.52M	44.04M	42.88M	44.25M	49.70M	56.97M	61.20M	74.98M	77.05M	-	88.51M	99.22M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	14.31M	27.36M	28.37M	15.58M	1.80M	311.00K	-	6.83M	32.17M	-	9.43M	0	0	7.50M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	138.58M	214.05M	279.30M	380.57M
Operating Income	-3.15M	9.71M	11.11M	-9.36M	-24.82M	-32.58M	-38.04M	-42.82M	-31.30M	-	-129.14M	-214.05M	-279.30M	-373.07M
EBITDA	-	-	-	-	-	-	-	-	-	-	-127.74M	-211.99M	-276.74M	-370.53M
Interest Expense	-	-	-	-	-	-	-	-	-	0	0	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-125.25M	-182.69M	-238.42M	-344.89M
Tax Provision	-	-	-	-	-	-	-	-	-	-	118.00K	-292.00K	-4.09M	1.02M
Net Income	-4.30M	12.03M	13.02M	-15.75M	-23.00M	-30.70M	-34.50M	-41.59M	-28.84M	-	-125.37M	-182.39M	-234.33M	-345.91M
Diluted EPS	-3.24	1.91	3.28	-1.10	-1.48	-1.72	-1.63	-	-0.81	-	-2.06	-2.73	-3.01	-4.36
R&D Expense	10.46M	12.30M	11.77M	15.15M	19.83M	25.57M	23.63M	38.84M	50.52M	75.46M	105.77M	167.51M	210.39M	300.94M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	54.49M	87.42M	63.95M	67.49M	46.12M	122.43M	147.70M	189.19M	-	754.15M	964.80M	798.14M	633.16M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	600.30M	644.96M	635.26M	560.65M
Cash & Equivalents	13.93M	60.16M	37.95M	72.03M	58.65M	17.09M	20.49M	67.75M	24.75M	45.01M	-	57.24M	148.64M	142.71M	199.16M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	-	-	-	-	986.00K	874.00K	1.47M	1.37M
Total Liabilities	-	-	30.37M	14.64M	2.92M	3.59M	10.19M	19.13M	55.72M	17.83M	-	32.65M	36.88M	43.24M	51.40M
Current Liabilities	-	-	18.20M	14.29M	2.78M	3.59M	4.08M	4.12M	43.38M	14.78M	-	22.70M	27.27M	35.59M	41.79M
Long Term Debt	-	-	-	-	-	-	6.10M	15.01M	10.89M	-	-	-	-	-	-
Total Debt	-	-	-	-	-	-	-	-	-	-	-	10.44M	10.90M	9.02M	7.94M
Total Equity	-86.32M	-89.86M	-78.37M	72.78M	61.03M	63.90M	35.93M	103.30M	91.98M	171.35M	-	721.50M	927.92M	754.90M	581.76M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	62.59M	75.37M	76.42M	80.01M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-	-	-	-28.73M	-34.72M	-4.71M	-48.12M	-	-101.03M	-151.11M	-181.39M	-279.12M
Investing Cash Flow	-	-	-	-	-	24.29M	-28.99M	-66.21M	-16.82M	-	-293.40M	-111.39M	165.00M	218.00M
Financing Cash Flow	-	-	-	-	-	7.07M	111.59M	27.52M	85.80M	-	278.47M	353.52M	12.13M	117.11M
Capital Expenditure	-526.00K	-156.00K	-1.53M	-551.00K	-279.00K	-315.00K	-507.00K	-1.24M	-2.64M	-	-2.89M	-5.62M	-3.08M	-799.00K
Free Cash Flow	-	-	-	-	-	-29.04M	-35.23M	-5.95M	-50.76M	-	-103.92M	-156.73M	-184.46M	-279.92M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-115.96M	91.03M	-4.26M	55.99M

Ratios (Annual)

Figures in %.

Metric	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-22.0%	35.5%	39.1%	-60.1%	-1,376.4%	-10,474.3%	-	-627.0%	-97.3%	-	-1,368.9%	-	-	-4,974.3%
Net Margin %	-30.1%	44.0%	45.9%	-101.1%	-1,275.5%	-9,872.7%	-	-609.1%	-89.7%	-	-1,328.9%	-	-	-4,612.1%
ROE %	4.8%	-15.4%	17.9%	-25.8%	-36.0%	-85.4%	-33.4%	-45.2%	-16.8%	-	-17.4%	-19.7%	-31.0%	-59.5%
ROCE %	-	26.8%	15.2%	-15.3%	-38.8%	-77.5%	-32.2%	-41.0%	-17.9%	-	-17.7%	-22.8%	-36.6%	-63.1%

Shareholding Pattern

Insiders

0.16%

Institutions

107.34%

Public Float

107.51%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	FMR, LLC	9.98%	9.65M	$351.57M
2	Blackrock Inc.	7.78%	7.52M	$274.12M
3	Avoro Capital Advisors LLC	5.98%	5.78M	$210.54M
4	Polar Capital Holdings PLC	4.73%	4.57M	$166.55M
5	Driehaus Capital Management, LLC	4.57%	4.42M	$161.01M
6	Jupiter Topco LLC	4.33%	4.19M	$152.56M
7	Price (T.Rowe) Associates Inc	3.36%	3.25M	$118.37M
8	JPMORGAN CHASE & CO	2.71%	2.62M	$95.38M
9	Capital International Investors	2.44%	2.36M	$86.06M
10	T. Rowe Price Investment Management, Inc.	2.24%	2.17M	$79.02M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for XENE

Google News hu, 22 Oct 2026

Xenon Pharmaceuticals Inc. (XENE) stock price, news, quote and history - Yahoo Finance Australia

<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTFA3aDFPOHRYaHI0ZTBJN0ZHQmdUVkVaclY0REF4Rlp3NURDUW1OTlhackxjcWVVQS14UTF1MXdSSjZtcVUtRDNDY1pZUk1SS1RiTXc?oc=5" target="_blank">Xenon Pharmaceuticals Inc. (XENE) stock price, news, quo…

Google News Wed, 21 Oct 2026

Xenon Pharmaceuticals Inc. (XENE) Stock Price, News, Quote & History - Yahoo! Finance Canada

<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE8yMnp4VzR1UU8yWUhHdDJoQzhYV2FhUFlxTVVjd0JEdzl5cnp6MGV5Nkl5X2lPVGIyZ0prV2FhVlVxdHQ3dkRjSEJHSE5jaG92VkE?oc=5" target="_blank">Xenon Pharmaceuticals Inc. (XENE) Stock Price, News, Quo…

Google News Wed, 30 Sep 2026

Xenon’s Insider Buying Tops $1.6M – XENE Stock Heads For Best Day In Over Month - Stocktwits

<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxNQUFZNVRaSXZ4RjB2SG10Z2VKMk5zaEIzc19TQkhwNl9NeHM5Vk5HVkhuM1dCbXlCZ0pTa21JVHMtT1NfOFAzZ21rWnk3eUh2VnIwSzNBeW1VVXBub0NsVmw2N1Q5aXh0bnMxRDlCUHV3MWhtRGg0cTRsMTYtbHhUWU4xSUFzaDNBV1lQOT…

Google News hu, 01 Oct 2026

Xenon rises on insider buys from CEO and CFO (XENE:NASDAQ) - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9pamwxbEtELTlkbXA4dDd6VDMtVm55ZHBvYzg4UzltYm1pMUJTS3FTQ0hBUHl3enVYNkxKZklPQUZhZVBGQ2dxaVJKOEpaTllfbGNJZGxUdnVlZm9YM1NCSFE5a2FudENNbnFaQ2JwTm1sN0M1emEwaDZn?oc=5" target="_blank">Xen…

Google News Fri, 18 Sep 2026

Why This Biotech Just Erased Its One-Day 50% Pop - Investor's Business Daily

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxOOC1ZSGdGaGdad2pRSGpDNkZ5TDR1c205R1BfMDBOMl9zaXpoRy1BQkpNOUl5YkVXc2VubGgxWXNSUnNUbkd4TVZFZTJwc251SEtKVHpnR1NZWE1aOU51dE05M0t2ekVUZTh2ODIyTFl3UGNOem5OY25ITjBpUFZuYUlKZ2Y5WXdjZDJjZz…

Google News Fri, 18 Sep 2026

XENE Stock Plummets as Xenon Pharmaceuticals Pauses Drug Trial - Barchart.com

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxPYUd3ZF9zaTJpekowS1lZZG1WNWthZ0tRRlpuc2hVZU9rNmgyOE90WUk3NU82d1A0QzhBNzdmSFMtU3IyN1JOT3I4YmRHbmo2RU95eUxoaktZYzc5a2lTOFpCSDFLcGdpcDdUOUR2cUVEaVFDeTU3UVdIQWthMjJhZE1GeWNfbVBIbVlRTU…

XENE — Frequently Asked Questions

What is the current share price of Xenon Pharmaceuticals Inc. (XENE)?

As of 2026-10-22 16:30 PDT, Xenon Pharmaceuticals Inc. (XENE) trades at $36.50 on NasdaqGM. Its 52-week range is $33.49 to $70.96.

What is the market capitalisation of XENE?

Xenon Pharmaceuticals Inc. (XENE) has a market capitalisation of $3.53B on NasdaqGM.

What is the P/E ratio of XENE?

XENE trades at a trailing price-to-earnings (P/E) ratio of -7.70. The industry average P/E is 25.61. Its price-to-book (P/B) ratio is 3.10.

What is the return on equity (ROE) of XENE?

XENE has a return on equity (ROE) of -43.62%. Its return on capital employed (ROCE) is -63.09%.

Is XENE a good stock to buy?

This page provides a data-driven analysis of Xenon Pharmaceuticals Inc. (XENE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Xenon Pharmaceuticals Inc. XENE R2KR3KPHARMA

Company Overview

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Xenon Pharmaceuticals Inc. (XENE) stock price, news, quote and history - Yahoo Finance Australia

Xenon Pharmaceuticals Inc. (XENE) Stock Price, News, Quote & History - Yahoo! Finance Canada

Xenon’s Insider Buying Tops $1.6M – XENE Stock Heads For Best Day In Over Month - Stocktwits

Xenon rises on insider buys from CEO and CFO (XENE:NASDAQ) - Seeking Alpha

Why This Biotech Just Erased Its One-Day 50% Pop - Investor's Business Daily

XENE Stock Plummets as Xenon Pharmaceuticals Pauses Drug Trial - Barchart.com

XENE — Frequently Asked Questions

What is the current share price of Xenon Pharmaceuticals Inc. (XENE)?

What is the market capitalisation of XENE?

What is the P/E ratio of XENE?

What is the return on equity (ROE) of XENE?

Is XENE a good stock to buy?

Explore More